Drug Type Antibody drug conjugate (ADC) |
Synonyms Tras-Gly5-PNU ADC |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC32H35NO13 |
InChIKeySLURUCSFDHKXFR-WWMWMSKMSA-N |
CAS Registry202350-68-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CH | 01 Oct 2016 |